Driver mutations such as those in CD79B, CDKN2A, MYD88, MYC, and CCND3, which are known to negatively affect the prognosis of DLBCL (36–40), were enriched in rrDLBCL. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.